Replies to post #172394 on Biotech Values

[jbog]

Iwfal,

What I clearly missed was not the success of their trial, but the prize that would be won with success.

Intercept isn't in the me-too or I'm a little better category like most of the bio's I follow, they intend to own the liver market.


Much like vertex's presence in the cf market or gilead's HIV market.